Expression of p63 and p73 in ameloblastomas

Journal of Oral Pathology and Medicine

Volumn 34, Issue 4, 2005, Pages 220-226

  Kumamoto, Hiroyuki ^a   Ohki, Kousuke ^a   Ooya, Kiyoshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Ameloblastoma; p53 homolog; p63; p73

Indexed keywords

MESSENGER RNA; PROTEIN P63; PROTEIN P73;

AMELOBLASTOMA; ARTICLE; BASEMENT MEMBRANE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; GENE FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SEQUENCE HOMOLOGY;

AMELOBLASTOMA; APOPTOSIS; BASEMENT MEMBRANE; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOOTH GERM; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 15944400019     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2005.00284.x     Document Type: Article

References (44)

1. Kramer IRH, Pindborg JJ, Shear M. WHO histological typing of odontogenic tumours. Berlin: Springer-Verlag, 1992; 11-27.
2. Melrose RJ. Benign epithelial odontogenic tumors. Semin Diagn Pathol 1999; 16: 271-87.
3. Eversole LR. Malignant epithelial odontogenic tumors. Semin Diagn Pathol 1999; 16: 317-24.
4. Sciubba JJ, Fantasia JE, Kahn LB. Tumors and cysts of the jaw. Washington, D.C.: Armed Forces institute of Pathology, 2001; 71-99.
5. Heikinheimo K, Jee KJ, Niini T, et al. Gene expression profiling of ameloblastoma and human tooth germ by means of a cDNA microarray. J Dent Res 2002; 81: 525-30.
6. Jaakelainen K, Jee KJ, Leivo I, Saloniemi I, Knuutila S, Heikinheimo K. Cell proliferation and chromosomal changes in human ameloblastoma. Cancer Genet Cytogenet 2002; 136: 31-7.
7. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93.
8. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-8.
9. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-72.
10. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-19.
11. Osada M, Ohba M, Kawahara C, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998; 4: 839-43.
12. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-16.
13. Marin MC, Kaelin WG Jr. p63 and p73: old members of a new family. Biochim Biophys Acta 2000; 1470: M93-M100.
14. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 2002; 22: 8659-68.
15. Hagiwara K, McMenamin MG, Miura K, Harris CC. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res 1999; 59: 4165-9.
16. Ichimiya S, Nimura Y, Kageyama H, et al. p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 1999; 18: 1061-6.
17. Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res 1998; 58: 2347-9.
18. Yokomizo A, Mai M, Tindall DJ, et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 1999; 18: 1629-33.
19. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999; 59: 3257-63.
20. Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999; 113: 1099-105.
21. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ. High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 2000; 19: 3439-44.
22. Hall PA, Campbell SJ, O'neill M, et al. Expression of the p53 homologue p63 α and ΔNp63 α in normal and neoplastic cells. Carcinogenesis 2000; 21: 153-60.
23. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 2000; 97: 5462-7.
24. Park BJ, Lee SJ, Kim JI, et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000; 60: 3370-4.
25. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157: 1769-75.
26. Hu H, Xia SH, Li AD, et al. Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int J Cancer 2002; 102: 580-3.
27. Kumamoto H. Detection of apoptosis-related factors and apoptotic cells in ameloblastomas: analysis by immunohistochemistry and an in situ DNA nick end-labelling method. J Oral Pathol Med 1997; 26: 419-25.
28. Kumamoto H, Ooya K. Immunohistochemical analysis of bcl-2 family proteins in benign and malignant ameloblastomas. J Oral Pathol Med 1999; 28: 343-9.
29. Kumamoto H, Kimi K, Ooya K. Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med 2001; 30: 309-15.
30. ARF proteins in ameloblastomas. J Oral Pathol Med 2004; 33: 292-9.
31. Celli J, Duijf P, Hamel BC, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999; 99: 143-53.
32. Brunner HG, Hamel BC, van Bokhoven H. The p63 gene in EEC and other syndromes. J Med Genet 2002; 39: 377-81.
33. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708-13.
34. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714-8.
35. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404: 99-103.
36. De Laurenzi V, Rossi A, Terrinoni A, et al. p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun 2000; 273: 342-6.
37. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002; 198: 417-27.
38. Thurfjell N, Coates PJ, Uusitalo T, et al. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004; 25: 27-35.
39. Slootweg PJ. p53 protein and Ki-67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. J Oral Pathol Med 1995; 24: 393-7.
40. Sandra F, Nakamura N, Mitsuyasu T, Shiratsuchi Y, Ohishi M. Two relatively distinct patterns of ameloblastoma: an anti-apoptotic proliferating site in the outer layer (periphery) and a pro-apoptotic differentiating site in the inner layer (centre). Histopathology 2001; 39: 93-8.
41. Kumamoto H, Ooya K. Expression of survivin and X chromosome-linked inhibitor of apoptosis protein in ameloblastomas. Virchows Arch 2004; 444: 164-70.
42. Douc-Rasy S, Barrois M, Echeynne M, et al. ΔN-p73 α accumulates in human neuroblastic tumors. Am J Pathol 2002; 160: 631-9.
43. White E, Prives C. DNA damage enables p73. Nature 1999; 399: 734-5.
44. Kumamoto H, Kimi K, Ooya K. Immunohistochemical analysis of apoptosis-related factors (Fas, Fas ligand, caspase-3 and single-stranded DNA) in ameloblastomas. J Oral Pathol Med 2001; 30: 596-602